Search results for " ARTERIAL HYPERTENSION"

showing 10 items of 29 documents

Obesity and Outcomes in COVID-19: When an Epidemic and Pandemic Collide.

2020

Obesity has reached epidemic proportions in the United States and in much of the westernized world, contributing to considerable morbidity. Several of these obesity-related morbidities are associated with greater risk for death with coronavirus disease 2019 (COVID-19). Severe acute respiratory syndrome coronavirus 2 penetrates human cells through direct binding with angiotensin-converting enzyme 2 receptors on the cell surface. Angiotensin-converting enzyme 2 expression in adipose tissue is higher than that in lung tissue, which means that adipose tissue may be vulnerable to COVID-19 infection. Obese patients also have worse outcomes with COVID-19 infection, including respiratory failure, n…

BMI body mass indexmedicine.medical_treatmentAdipose tissue030204 cardiovascular system & hematologyCHD coronary heart diseaseHF heart failureUS United States0302 clinical medicineRAAS renin-angiotensin-aldosterone systemPandemicMedicine030212 general & internal medicineCDC Centers for Disease Control and PreventionCOVID-19 coronavirus disease 2019TNF tumor necrosis factorHFpEF HF with preserved ejection fractionCV cardiovascularGeneral MedicinePrognosisICU intensive care unitPA physical activityMetS metabolic syndromePAH pulmonary arterial hypertensionCoronavirus Infectionsmedicine.medical_specialtyAF atrial fibrillationACE angiotensin-converting enzymePneumonia ViralCVD cardiovascular diseaseSARS-CoV-2 severe acute respiratory syndrome coronavirus 2ArticleSeverity03 medical and health sciencesBetacoronavirusInternal medicineIPF idiopathic pulmonary fibrosisHumansObesityMortalityHTN hypertension or hypertensivePandemicsMechanical ventilationAng II angiotensin IIbusiness.industrySARS-CoV-2CKD chronic kidney diseaseCOVID-19T2DM type 2 diabetes mellitusmedicine.diseaseAngiotensin IIObesityIL interleukinPneumoniaRespiratory failureMetabolic syndromebusinessSNS sympathetic nervousMayo Clinic proceedings
researchProduct

RELATIONSHIPS BETWEEN SHORT-TERM BLOOD PRESSURE VARIABILITY AND EARLY RENAL DYSFUNCTION IN ESSENTIAL HYPERTENSIVE PATIENTS

2014

Blood pressure variabilityBlood pressure variability; Ambulatory Blood pressure monitoring; renal damage; arterial hypertensionAmbulatory Blood pressure monitoringarterial hypertensionrenal damage
researchProduct

ABSENCE OF RELATIONSHIPS BETWEEN SHORT-TERM BLOOD PRESSURE VARIABILITY AND EARLY RENAL DYSFUNCTION IN HYPERTENSION

2014

Blood pressure variability

Blood pressure variabilityambulatory blood pressure monitoring arterial hypertension.renal disease
researchProduct

Role of curcumin in idiopathic pulmonary arterial hypertension treatment: A new therapeutic possibility

2013

The idiopathic pulmonary arterial hypertension is a complex disease that mainly affects pulmonary arterial circulation. This undergoes a remodeling with subsequent reduction of flow in the small pulmonary arteries. Because of this damage an increased vascular resistance gradually develops, and over time it carries out in heart failure. The inflammatory process is a key element in this condition, mediated by various cytokines. The inflammatory signal induces activation of NF-κB, and prompts TGF-β-related signaling pathway. Clinical evolution leads to progressive debilitation, greatly affecting the patient quality of life. The actual therapeutic approaches, are few and expensive, and include …

CurcuminSettore MED/06 - Oncologia MedicaHypertension PulmonaryComplex diseaseInflammationPharmacologyModels Biologicalchemistry.chemical_compoundTransforming Growth Factor betamedicineidiopathic pulmonary arterial hypertensionHumansFamilial Primary Pulmonary HypertensionCurcumin; idiopathic pulmonary arterial hypertensionbusiness.industryIdiopathic Pulmonary Arterial HypertensionNF-kappa BPhosphodiesteraseGeneral Medicinemedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareIncreased vascular resistancechemistryHeart failureCurcuminVascular Resistancemedicine.symptomSignal transductionbusinessSignal Transduction
researchProduct

Knowledge gaps and future directions in cognitive functions in children and adolescents with primary arterial hypertension: A systematic review

2022

Arterial hypertension (AH) among adults is known to be associated with worse cognitive outcomes. Similarly, children and adolescents with AH could be expected to underperform during neuropsychological evaluations when compared with healthy peers. Our aims were to review the existing literature on cognitive functioning among children and adolescents with primary AH and to identify what additional evidence may be needed to substantiate the impact of hypertension on poor cognitive outcomes in this population. We conducted a systematic review of articles in PubMed and Web of Science published before 17 January 2022, reporting on cognitive testing among children and adolescents with primary AH. …

Funcions executives (Neuropsicologia)JovesPressió sanguíniaNeuropsicologia pediàtricaChildhoodAdolescènciaAdolescencePediatric neuropsychologyBlood pressureblood pressure ; primary arterial hypertension ; executive functions ; neuropsychology ; pediatrics ; childhood ; adolescence ; HyperChildNETExecutive functions (Neuropsychology)Cardiology and Cardiovascular MedicineInfantsInfància
researchProduct

Health Implications of Judo Training

2021

Although current physical activity (PA) guidelines regarding aerobic and anaerobic training are helpful for the population at large, many individuals prefer to engage in alternative forms of PA such as combat sports. As both a martial art and sport, judo is a physically demanding form of PA that potentially offers a novel experience, consequently leading to greater PA adherence. This study aimed to thoroughly search the existing literature to determine the health benefits of judo-specific training. PubMed and Web of Science were searched for original research studies. Only peer-reviewed studies that examined the effects of judo training in males and females aged 18–35 were included in the s…

Gerontologyobesityarterial hypertensionGeography Planning and DevelopmentPopulationTJ807-830Management Monitoring Policy and LawHealth benefitsTD194-195aerobic powerRenewable energy sourcesJUDÔ03 medical and health sciences0302 clinical medicinerespiratory functionRespiratory functionGE1-35010. No inequalityeducationAerobic power; Arterial hypertension; Bone mineral density; Cardiac remodeling; Obesity; Respiratory functionHealth implicationseducation.field_of_studyMartial artsbiologyEnvironmental effects of industries and plantsRenewable Energy Sustainability and the EnvironmentAthletes030229 sport sciencesbiology.organism_classificationEnvironmental sciencescardiac remodelingPsychologybone mineral densityAnaerobic exerciseInclusion (education)human activities030217 neurology & neurosurgerySustainability
researchProduct

Hypertensive heart disease: diagnostic and therapeutic guidelines

2008

Herat disease arterial hypertension
researchProduct

Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension:A Double-Blind Placebo-controlled Clinical Trial

2020

Rationale: Oral treprostinil improves exercise capacity in patients with pulmonary arterial hypertension (PAH), but the effect on clinical outcomes was unknown.\ud \ud Objectives: To evaluate the effect of oral treprostinil compared with placebo on time to first adjudicated clinical worsening event in participants with PAH who recently began approved oral monotherapy.\ud \ud Methods: In this event-driven, double-blind study, we randomly allocated 690 participants (1:1 ratio) with PAH to receive placebo or oral treprostinil extended-release tablets three times daily. Eligible participants were using approved oral monotherapy for over 30 days before randomization and had a 6-minute-walk dista…

MaleAdministration OralOral treprostinilCritical Care and Intensive Care MedicinePulmonary arterial hypertension[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractcombination therapyoralepoprostenol0302 clinical medicinepulmonary arterial hypertensionmiddle agedClinical endpointdouble-blind methodMESH: Double-Blind MethodFamilial Primary Pulmonary Hypertension030212 general & internal medicinehumansMESH: AgedMESH: Middle AgedEpoprostenol/analogs & derivativesadultHazard ratioMiddle Aged[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciencesantihypertensive agents3. Good healthagedfemaleMESH: Young Adultoral treprostinilMESH: Administration Oralyoung adultFemalePulmonary Arterial Hypertension/drug therapymedicine.drugAdultPulmonary and Respiratory MedicineMESH: Pulmonary Arterial Hypertensionmedicine.medical_specialtyRandomizationAdolescentclinical study; combination therapy; oral treprostinil; pulmonary arterial hypertension; sequential therapy; administration oral; adolescent; adult; aged; antihypertensive agents; double-blind method; epoprostenol; female; humans; male; middle aged; placebos; pulmonary arterial hypertension; young adultSequential therapyMESH: PlacebosMESH: EpoprostenolLower riskPlaceboadministrationClinical studyYoung Adult03 medical and health sciencesDouble-Blind Method[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmaleInternal medicineplacebosmedicineHumansCombination therapyAdverse effectPlacebos/therapeutic useAgedMESH: AdolescentPulmonary Vascular DiseaseMESH: Antihypertensive AgentsMESH: Humanssequential therapybusiness.industryMESH: AdultOriginal Articlesclinical studyMESH: MaleClinical trial030228 respiratory systemadolescentAntihypertensive Agents/administration & dosagebusinessMESH: FemaleTreprostinil
researchProduct

Usefulness of Right Ventricular to Pulmonary Circulation Coupling as an Indicator of Risk for Recurrent Admissions in Heart Failure With Preserved Ej…

2019

In recent years, the study of right ventricular (RV) to pulmonary circulation (PC) coupling in heart failure with preserved ejection fraction (HFpEF) has been a matter of special interest. Tricuspid annular plane systolic excursion (TAPSE) to pulmonary artery systolic pressure (PASP) ratio has emerged as a reliable noninvasive index of RV to PC coupling. Thus, we hypothesized that TAPSE/PASP would be a predictor of readmission burden in HFpEF. One thousand one hundred and twenty seven consecutive HFpEF patients discharged for acute HF were included. In 367 patients (32.6%), PASP could not be accurately measured by echocardiography, leaving the final sample size to be 760 patients. Negative …

MaleRiskmedicine.medical_specialtyPulmonary CirculationVentricular Dysfunction Right030204 cardiovascular system & hematologyPulmonary ArteryCohort Studies03 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicinemedicine.arterymedicineHumansArterial Pressure030212 general & internal medicineProspective StudiesProspective cohort studyAgedAged 80 and overHeart FailurePulmonary Arterial Hypertensionright ventriculabusiness.industryStroke VolumeStroke volumeMiddle AgedPrognosispreserved ejection fractionEchocardiography Dopplersystolic excursionHospitalizationBlood pressurepulmonary circulationCohortPulmonary arteryCardiologyFemaleTricuspid ValveCardiology and Cardiovascular MedicineHeart failure with preserved ejection fractionbusinessCohort studyThe American journal of cardiology
researchProduct

Potential of the EPA/DHA 6/1 formulation to prevent endothelial dysfunction and cardiopulmonary remodeling in pulmonary arterial hypertension in rats

2016

Pulmonary arterial hypertension (PAH) is characterized by remodeling of the small pulmonary arteries leading to a progressive increase in pulmonary vascular resistance and right ventricular failure. Pulmonary endothelial dysfunction, inflammation and oxidative stress promote the development of pulmonary hypertension. Omega-3 polyunsaturated fatty acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acids (DHA) have been shown to protect the cardiovascular system and reduce inflammation and oxidative stress. The present study evaluate the potential of EPA:DHA 6:1 to prevent monocrotaline-induced PAH in rats. EPA:DHA 6:1 treatment (500 mg/kg/d, p.o) prevented the MCT-induced mean pul…

MonocrotalineAcide eicosapentaénoîque (EPA)Dysfonction endothélialeInflammation and oxidative stress[CHIM.THER] Chemical Sciences/Medicinal ChemistryDocosahexaenoic acids (DHA)Hypertension artérielle pulmonaireRemodelage pulmonairePulmonary arterial hypertensionAcide docosahexaénoïque (DHA)Remodelage du ventricule droitInflammation et stress oxydant[SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyCardiopulmonary remodelinglipids (amino acids peptides and proteins)Pulmonary endothelial dysfunctionEicosapentaenoic acid (EPA)
researchProduct